Johnson & Johnson (JNJ) Offering Possible 8.34% Return Over the Next 23 Calendar Days

This post was originally published on this site

Johnson & Johnson’s most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $170.00 short call and a strike $180.00 long call offers a potential 8.34% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $9.23 would be incurred if the stock rose above the $180.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now
Tue, 21 Sep 2021 11:25:00 +0000
Following Warren Buffett’s stock picks seems like a splendid idea. Known as the Oracle of Omaha, he’s built up quite an impressive track record in his long investing career running a partnership, then as head of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), since 1970. As a cautionary note, you shouldn’t buy stocks merely because someone else owns them, even if that person is Warren Buffett.

Coronavirus tally: Global cases of COVID-19 top 229 million and J&J says booster vaccine shot increases antibodies
Tue, 21 Sep 2021 10:57:12 +0000
The global tally for the coronavirus-borne illness climbed above 229 million on Tuesday, while the death toll rose to 4.70 million, according to

Johnson & Johnson says Phase 3 trial data confirms ‘strong and long-lasting’ protection from COVID-19 vaccine
Tue, 21 Sep 2021 10:42:19 +0000
Johnson & Johnson said Tuesday data from a Phase 3 trial and real-world evidence confirm that its single-shot COVID-19 vaccine offers strong and long-lasting protection against hospitalization and death. The company said further data shows that a booster shot offers increased protection. Data shows 94% protection in the U.S. with a booster given at two months, a four-fold increase in antibodies when given at two months and a 12-fold increase when given at six months. “The safety profile of the v

J&J says second shot boosts protection for moderate-severe COVID-19 to 94%
Tue, 21 Sep 2021 10:30:01 +0000
Johnson & Johnson said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease. The data will help J&J make its case to U.S. regulators for a booster shot even as the company stresses the durability of its single-shot vaccine as a tool to ease the global pandemic. President Joe Biden is pushing for booster shots in the face of surging hospitalizations caused by the Delta variant and J&J, the only drugmaker with a single-shot COVID-19 vaccine approved in the United States, has been under pressure to produce evidence on the effectiveness of an additional dose.

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Tue, 21 Sep 2021 10:30:00 +0000
Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster.

Be Sociable, Share!

Related Posts